Longboard Pharmaceuticals has made a notable name for itself in the pharmaceutical industry, particularly in the realm of neurological diseases. Despite its relatively short history, the company was initially known for its development of small-molecule drug candidates aimed at treating conditions like epilepsy and other neurological disorders. However, as with many startups, the company’s journey has seen significant changes. The question that arises is, “Is Longboard Pharmaceuticals still in business?” The answer lies in the company’s transformation and acquisition by a larger pharmaceutical entity. This article explores Longboard’s background, its acquisition by Lundbeck, and how this transition has impacted the company’s operations and future prospects.
A Little Background About Longboard Pharmaceuticals
Longboard Pharmaceuticals was founded with a mission to develop novel treatments for neurological diseases, focusing primarily on epilepsy and developmental encephalopathies. The company’s early success in the pharmaceutical industry stemmed from its promising drug pipeline, which targeted various neurological conditions using small-molecule drug candidates.
The company’s flagship candidate, bexicaserin, was designed to address seizures associated with developmental and epileptic encephalopathies, a group of rare, severe conditions that are often difficult to treat with standard therapies. Through its innovative research and clinical trials, Longboard was poised to make significant strides in the neuroscience field.
Despite these promising developments, the company was always navigating the challenges faced by early-stage biopharmaceutical firms, including securing funding, expanding its research, and scaling its operations. As the company grew, it eventually attracted the attention of larger pharmaceutical entities seeking to expand their own portfolios of neurological treatments.
Is Longboard Pharmaceuticals Still in Business?
As of 2026, Longboard Pharmaceuticals is indeed still in business, but with a significant transformation. While it is no longer an independent entity operating on its own, it continues to exist under new ownership. In December 2024, H. Lundbeck A/S, a global pharmaceutical company specializing in neurological and psychiatric treatments, acquired Longboard Pharmaceuticals.
This acquisition marked the end of Longboard’s time as an independent entity, but it also opened the door for its continued development and integration into a much larger company with the resources to advance its drug pipeline. While Longboard no longer operates as a separate entity on the stock market or under its original brand, its operations and clinical programs are very much alive and thriving under the Lundbeck umbrella.
Acquisition by Lundbeck
In a strategic move to strengthen its presence in the neurological drug market, Lundbeck acquired Longboard Pharmaceuticals in 2024. This acquisition allowed Lundbeck to integrate Longboard’s promising drug candidates into its existing portfolio, particularly those related to rare and hard-to-treat neurological conditions.
Lundbeck, which has a long-standing history in the treatment of brain diseases such as depression, Alzheimer’s, and schizophrenia, saw an opportunity to enhance its research and development pipeline with Longboard’s innovative therapies. The acquisition also provided Longboard’s clinical trials and drug development programs with the financial backing and infrastructure needed for expansion and success in the global pharmaceutical market.
For Longboard Pharmaceuticals, being acquired by a company like Lundbeck offered a chance to continue its work with increased resources and support, allowing the drug candidates to reach a wider audience and possibly become more commercially viable.
Current Business Operations
Today, Longboard Pharmaceuticals continues its operations, but under the larger umbrella of Lundbeck. As part of Lundbeck, the company’s focus remains on developing therapies for neurological diseases, with an emphasis on epilepsy, developmental encephalopathies, and other neurological disorders.
One key advantage for Longboard as a subsidiary of Lundbeck is the access to greater resources, including clinical trial funding, regulatory expertise, and market access. Under Lundbeck’s ownership, Longboard is able to continue progressing its pipeline with a level of stability and expertise that was harder to achieve as a smaller independent entity.
While the day-to-day operations may now fall under Lundbeck’s broader organizational structure, Longboard’s leadership and scientific teams remain involved in advancing the company’s original vision—developing novel, effective treatments for neurological disorders. The ongoing research and clinical trials for Longboard’s drug candidates continue, contributing to Lundbeck’s robust portfolio of neurological treatments.
Key Products and Drug Development Pipeline
Longboard Pharmaceuticals is best known for its work on bexicaserin, a drug designed to treat seizures associated with developmental and epileptic encephalopathies. While bexicaserin remains in development, it is now part of Lundbeck’s broader pipeline of neurological treatments.
In addition to bexicaserin, Longboard has developed other small-molecule drug candidates targeting various neurological conditions, particularly those that affect patients with rare diseases. Lundbeck has continued to support the advancement of these drug candidates through clinical trials and regulatory submissions.
Lundbeck’s acquisition of Longboard has expanded its research capabilities, particularly in the area of rare neurological diseases, where treatments are often scarce. This acquisition has brought Longboard’s promising therapies under the guidance of a company with a wealth of experience in bringing innovative neurological drugs to market.
Public and Market Status
Longboard Pharmaceuticals is no longer an independent publicly traded company. After the acquisition by Lundbeck, Longboard ceased to exist as a standalone entity on the stock market. However, its research and development efforts continue to contribute to Lundbeck’s public status, particularly in the field of neurological treatments.
For investors, the acquisition has shifted the focus from Longboard as a separate, emerging pharmaceutical company to a smaller but important part of Lundbeck’s growing portfolio. Lundbeck’s shareholders now benefit from Longboard’s ongoing drug development pipeline, which promises to offer new treatments for neurological conditions with unmet needs.
Although Longboard is no longer an independent brand, its legacy and contributions to the field of neuroscience continue to resonate within the broader Lundbeck organization.
Impact of the Acquisition on Longboard’s Operations
The acquisition of Longboard Pharmaceuticals by Lundbeck has had a significant impact on the company’s operations. First and foremost, it has provided Longboard with access to greater resources, including funding, regulatory expertise, and a larger network for clinical trials and market access. This has been particularly important for advancing Longboard’s drug candidates, which are now more likely to reach the market with the support of a global pharmaceutical company.
For Longboard’s employees and leadership, the acquisition has likely meant a shift in organizational culture and structure. However, it has also provided them with the stability and resources needed to continue their work, without the financial pressures that often come with being a small biotech firm.
In terms of drug development, the acquisition has allowed Longboard’s therapies to be integrated into Lundbeck’s existing pipeline, with the aim of bringing these treatments to a wider patient base. This merger has helped Longboard scale its operations and contribute to Lundbeck’s overall goals in the field of neuroscience.
Conclusion
Longboard Pharmaceuticals may no longer exist as an independent company, but it continues to thrive under the umbrella of Lundbeck. The company’s promising drug pipeline, including treatments for rare neurological diseases like epilepsy, remains a key focus of Lundbeck’s ongoing research and development efforts.
The acquisition by Lundbeck has provided Longboard with the resources, infrastructure, and expertise needed to continue its work on innovative therapies, ensuring that its contributions to the neurological field will have a lasting impact. While Longboard’s status as an independent company has changed, its legacy lives on through its work with Lundbeck, and its future prospects remain bright within the global pharmaceutical market.
As the industry evolves, Longboard’s integration into Lundbeck will continue to shape the future of neurological treatments, benefiting patients with conditions that have long been underserved by traditional therapies.
Also Read:
- Is Guy Phoenix Still in Business?
- Is Count’s Kustoms Still in Business?
- Cerebral Success Still in Business
